News Initiator Pharma A/S

Equities

INIT

DK0060775872

Market Closed - Nasdaq Stockholm Other stock markets 04:29:39 08/05/2024 pm IST			5-day change	1st Jan Change
9.26 ^SEK	-1.70%		+3.81%	+0.22%

23/02	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
21/02	Initiator Pharma Issues New Shares for Debt Conversion	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notice to AGM in Initiator Pharma	02/05	AQ
Annual report and Remuneration report 2023 for Initiator Pharma A/S	02/05	AQ
Initiator Pharma's pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	15/04	AQ
Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology	12/04	AQ
Initiator Pharma - Q4 2023 – Breathing optimism	23/02	AQ
INITIATOR PHARMA: YEAR END REPORT 2023	23/02	AQ
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02	CI
Initiator Pharma Issues New Shares for Debt Conversion	21/02	MT
MAC Clinical Research converts its receivable into shares in Initiator Pharma	21/02	AQ
Initiator Pharma A/S - Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	24/01	AQ
Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021	23/01	AQ
Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts	08/01	AQ
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	08/01	CI
Initiator Pharma Q3 - A historical quarter	10/11	AQ
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	07/11	AQ
Initiator Pharma - Positive Phase IIb results	10/23/10	AQ
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	09/23/09	AQ
Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine	06/23/06	AQ
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	06/23/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Initiator Pharma A/S

Equities

INIT

DK0060775872

Summary

Filters